Illumina, Inc. vs Snowflake Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Snowflake Inc trades at $368.89 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 3× Illumina, Inc.'s market cap, and Snowflake Inc is more actively traded (3,986,549 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Snowflake Inc for 54 Days on average.
| ILMN | SNOW | |
|---|---|---|
Market Cap | $39.95B | $121.15B |
Volume | 3,169,503 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $293.69 | $368.89 |
52-Week Low | $91.00 | $121.11 |
Typical Hold Time | 83 Days | 54 Days |
Enterprise Value | $41.31B | $121.57B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $264.40, down 1.25% on the day but remains near its 52-week high of $278.99, reflecting strong momentum with a 94.9% YTD gain. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Fundamentals show a significant turnaround, with net income reaching $850 million in 2025 after prior losses, supported by robust gross margins of 66.38%. Technical indicators are bullish overall, with key support at $257 and resistance at $268.
The outlook for ILMN is positive, driven by earnings momentum, inclusion in the S&P 500, and strategic AI initiatives in genomics. However, risks include high valuation multiples, such as a P/E of 49.36, and potential margin pressure from cost volatility. Analyst consensus is bullish with a 54% buy rating, though the consensus price target of $241 suggests limited near-term upside from current levels.
Snowflake (SNOW) trades at $343.40, up 3.17% with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $3.63 billion in 2025 but remains unprofitable with a net income margin of -20.07%. Recent positive developments include strategic partnerships with UiPath and a $3.75 billion convertible note offering to fund growth initiatives.
Snowflake presents a growth investment opportunity with strong analyst support (81% buy ratings) and a $418 price target, but faces execution risks from persistent losses and high valuation multiples. The stock's upside depends on continued revenue expansion and path to profitability amid competitive cloud data market pressures.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →